Doxribtimine

Doxribtimine

SCHEMBL887722

Cc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O.O=P(O)(O)O.O=P(O)(O)O.O=P(O)(O)O.O=P(O)(O)O

nearest known ligand 0.71

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

P

The experimentally established mechanism targets of Doxribtimine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
TK1 P04183 4/20 0.67
LMNA P02545 3/20 0.67
SMN1; SMN2 Q16637 1/20 0.67
POLB P06746 1/20 0.67
TK2 O00142 1/20 0.65
TSHR P16473 2/20 0.65
ALB P02768 1/20 0.65
PKM P14618 1/20 0.65
BLM P54132 1/20 0.65
PMP22 Q01453 1/20 0.65
CYP2D6 P10635 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Doxribtimine SCHEMBL8075845 1.00 TK1 (0.67) TK1LMNASMN1; SMN2POLBTK2
Doxribtimine SCHEMBL77830 1.00 TK1 (0.67) TK1LMNASMN1; SMN2POLBTK2
Doxribtimine SCHEMBL176363 1.00 TK1 (0.67) TK1LMNASMN1; SMN2POLBTK2
Doxribtimine SCHEMBL21682515 1.00 TK1 (0.67) TK1LMNASMN1; SMN2POLBTK2
Doxribtimine SCHEMBL9687292 0.99 TK1 (0.66) TK1LMNASMN1; SMN2POLBTK2
Doxribtimine SCHEMBL29150139 0.98 TK1 (0.65) TK1LMNASMN1; SMN2POLBTK2
Doxribtimine SCHEMBL7576317 0.97 TK1 (0.66) TK1LMNASMN1; SMN2POLBTK2
Doxribtimine SCHEMBL5692278 0.97 TK1 (0.66) TK1LMNASMN1; SMN2POLBTK2
Doxribtimine SCHEMBL9386574 0.97 TK1 (0.66) TK1LMNASMN1; SMN2POLBTK2
Doxribtimine SCHEMBL9385913 0.97 TK1 (0.66) TK1LMNASMN1; SMN2POLBTK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8058031-B2 Labeled nucleotide analogs and uses therefor PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) 2011-11-15 US disclosed
US-20110059450-A1 LABELED NUCLEOTIDE ANALOGS AND USES THEREFOR PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) 2011-03-10 US disclosed
US-7777013-B2 Labeled nucleotide analogs and uses therefor PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) 2010-08-17 US disclosed
US-20090018324-A1 LABELED NUCLEOTIDE ANALOGS AND USES THEREFOR PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) 2009-01-15 US disclosed
US-7405281-B2 Fluorescent nucleotide analogs and uses therefor PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) 2008-07-29 US disclosed
EP-1937702-A2 LABELED NUCLEOTIDE ANALOGS AND USES THEREFOR Pacific Biosciences of California, Inc. (US) 2008-07-02 EP disclosed
WO-2007041342-A2 LABELED NUCLEOTIDE ANALOGS AND USES THEREFOR PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) 2007-04-12 WO disclosed
US-20070072196-A1 Fluorescent nucleotide analogs and uses therefor PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) 2007-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070072196-A1 Fluorescent nucleotide analogs and uses therefor DNTT, POLRMT, RNGTT TK1 29/4885LMNA 1033/4885SMN1; SMN2 3743/4885
US-20090018324-A1 LABELED NUCLEOTIDE ANALOGS AND USES THEREFOR POLRMT, DNTT, NUDT1 TK1 12/4885LMNA 1292/4885SMN1; SMN2 3838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.